
Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Interstitial nephritis medical therapy
Introduction
Overview
Overview
The mainstay of treatment for tubulointerstitial nephritis is discontinuation of potentially offending agent. The majority of patients due to drug-induced interstitial nephritis, improve spontaneously with supportive care. However, renal function may not return to baseline. In conditions with persisting renal failure it is recommended to obtain a renal biopsy and trial of glucocorticoids therapy for patients with AIN on biopsy.
Medical Therapy
Medical Therapy
The mainstay of treatment for tubulointerstitial nephritis is discontinuation of potentially offending agent. Additional treatment measures include:
- Supportive care:
- Control of blood pressure with anti-hypertensives.
- Correction of electrolyte imbalances
- No additional measures are recommend for patients who responded to supportive measures
- In conditions with persisting renal failure it is recommended to obtain a renal biopsy and trial of glucocorticoids therapy for patients with AIN on biopsy..[1][2]
- Preferred regimen (1): Prednisone 1 mg/kg per day PO or equivalent IV dose (maximum of 40 to 60 mg)
- Note: Recommended for 1-2 weeks, followed by gradual tappering.[3]
- Alternative regimen (1): Mycophenolate mofetil[4]
- Note: Indicated in glucocorticoid resistant or contraindicated cases.
- Preferred regimen (1): Prednisone 1 mg/kg per day PO or equivalent IV dose (maximum of 40 to 60 mg)
References
References
- ↑ Baker, R. J.; Pusey, C. D. (2004). “The changing profile of acute tubulointerstitial nephritis”. Nephrology Dialysis Transplantation. 19 (1): 8–11. doi:10.1093/ndt/gfg464. ISSN 0931-0509.
- ↑ Michael R. Clarkson, Louise Giblin, Fionnuala P. O’Connell, Patrick O’Kelly, Joseph J. Walshe, Peter Conlon, Yvonne O’Meara, Anthony Dormon, Eileen Campbell & John Donohoe (2004). “Acute interstitial nephritis: clinical features and response to corticosteroid therapy”. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association – European Renal Association. 19 (11): 2778–2783. doi:10.1093/ndt/gfh485. PMID 15340098. Unknown parameter
|month=ignored (help) - ↑ J. Rossert (2001). “Drug-induced acute interstitial nephritis”. Kidney international. 60 (2): 804–817. doi:10.1046/j.1523-1755.2001.060002804.x. PMID 11473672. Unknown parameter
|month=ignored (help) - ↑ Dean C. Preddie, Glen S. Markowitz, Jai Radhakrishnan, Thomas L. Nickolas, Vivette D. D’Agati, Joshua A. Schwimmer, Mark Gardenswartz, Raquel Rosen & Gerald B. Appel (2006). “Mycophenolate mofetil for the treatment of interstitial nephritis”. Clinical journal of the American Society of Nephrology : CJASN. 1 (4): 718–722. doi:10.2215/CJN.01711105. PMID 17699278. Unknown parameter
|month=ignored (help)
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Mohsen Basiri M.D.
